UCB, a global biopharmaceutical company, today announced the CHMP (Committee for Medicinal Products for Human Use) has issued a positive opinion for the self-administration of RYSTIGGO® ...

VMD response to concerns raised following media reports of serious adverse events in cats administered Solensia. The VMD is aware of media reports and ...

Quipt Home Medical Corp. (the "Company") , a U.S. based home medical equipment provider, focused on end-to-end respiratory care, acknowledges receipt of a notice from Philotimo Fund, LP, an entity ...

The reassessment of Leqembi’s safety data follows the agency’s previous recommendation of the drug for use in the EU.

Biogen and Eisai said they believe that EC's requests can be addressed with existing information, and that no new safety signals have been identified for Leqembi. The U.S. Food and Drug Administration ...

Bristol Myers Squibb today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Breyanzi® (lisocabtagene maraleucel; ...

Data from the Phase 3 PALOMA-3 study showed non-inferiority to intravenous administration meeting both co-primary pharmacokinetic (PK) endpoints, as well as a five-fold reduction in infusion-related ...

U.S. made products will soon be more expensive in Canada ... goods will be affected with $30 billion of those products subject to tariffs on Feb. 4th and the remainder 21 days later to give ...

The federal government has released the full list of U.S. products subject to 25 per cent import tariffs, effective Tuesday, in retaliation to U.S. President Donald Trump’s sweeping tariffs on ...

Bristol Myers Squibb (NYSE: BMY) today reports results for the fourth quarter and full year of 2024. "We made good progress in 2024, which was capped by a fourth ...